Joanne E. Tomassini

10.7k citations

103 papers · 4.9k indexed · 2 hit papers · h-index 35

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- SARS-CoV-2 and COVID-19 Research

Papers in

Endocrinology, Diabetes and Metabolism 34
- Diabetes, Cardiovascular Risks, and Lipoproteins 33
Virology 7

Co-authors: Andrew M. Tershakovec Richard J. Colonno David Neff Daria J. Hazuda Osvaldo Flores J C Hastings Gary Lee Harold Bays
Journals: Journal of clinical lipidology (18 papers)Atherosclerosis (8 papers)The American Journal of Cardiology (7 papers)Journal of the American College of Cardiology (6 papers)Antimicrobial Agents and Chemotherapy (5 papers)
Partner nations: United States Italy United Kingdom

In The Last Decade

Joanne E. Tomassini

102 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

A Bivalent Omicron-Containing Booster Vaccine against Covid-19 2022 · 346 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 New England Journal of Medicine
2017 Clinical Cancer Research

Peers

Countries citing papers authored by Joanne E. Tomassini

Since Specialization

Citations

This map shows the geographic impact of Joanne E. Tomassini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne E. Tomassini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne E. Tomassini more than expected).

Fields of papers citing papers by Joanne E. Tomassini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne E. Tomassini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne E. Tomassini. The network helps show where Joanne E. Tomassini may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joanne E. Tomassini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joanne E. Tomassini Line = papers co-authored together Joanne E. Tomassini links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1939. Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves Open Forum Infectious Diseases ·Dean Follmann, Xiaowei Wang, Peter B. Gilbert, Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Mary Marovich, Holly Janes, Weiping Deng, Frances Priddy, Avika Dixit, Joanne E. Tomassini, Rituparna Das, Jacqueline M. Miller, Haiyu Zhou	2023	0
2	A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus Nature Medicine ·Allison August, Husain Attarwala, Sunny Himansu, K. Schubert, 范德清, Rolando Pajón, Shu Han, Jean‐Michel Lecerf, Joanne E. Tomassini, Marjie Hard, Leon M. Ptaszek, James E. Crowe, Tal Zaks	2021	118
3	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer Clinical Cancer Research ·Jennifer H. Yearley, Christopher J. Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan D. Cheng, Laura Q.M. Chow, Tanguy Y. Seiwert, Masahisa Handa, Joanne E. Tomassini, Terrill K. McClanahan Hit paper breakdown →	2017	453
4	CHOLESTEROL IN REMNANT-LIPOPROTEINS AS MEASURED BY DIFFERENT Journal of the American College of Cardiology ·Peter P. Tóth, Harold Bays, W. Virgil Brown, Joanne E. Tomassini, Ворожнин Владимир Сергеевич, Adam B. Polis, Andrew M. Tershakovec	2015	2
5	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey Lipids in Health and Disease ·Michel Krempf, Ross J. Simpson, Dena Rosen Ramey, Philippe Brudi, Hilde Giezek, Joanne E. Tomassini, Raymond Lee, Michel Farnier	2015	15
6	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome Journal of clinical lipidology ·Jennifer G. Robinson, Christie M. Ballantyne, Willa A. Hsueh, Jeffrey B. Rosen, Jianxin Lin, Arvind Shah, Joanne E. Tomassini, Robert S. Lowe, Andrew M. Tershakovec	2013	12
7	Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy Vascular Health and Risk Management ·JoAnne M. Foody, Peter P. Tóth, Shiva Sajjan, Dena Rosen Ramey, Maksim Kudrinski, Andrew M. Tershakovec, Alireza Shahrestani, Henry Hu, Joanne E. Tomassini	2013	32
8	CHANGES IN LIPOPROTEIN PARTICLE NUMBER WITH EZETIMIBE/SIMVASTATIN COADMINISTERED WITH EXTENDED-RELEASE NIACIN IN PATIENTS WITH TYPE II HYPERLIPIDEMIA Journal of the American College of Cardiology ·Anh Lê, Ran Jin, Andrew M. Tershakovec, David Neff, Joanne E. Tomassini, James D. Otvos, Peter W.F. Wilson	2012	1
9	Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis Journal of Atherosclerosis and Thrombosis ·William F. Keane, Joanne E. Tomassini, David Neff	2012	79
10	Lipid Abnormalities in Patients with Chronic Kidney Disease Contributions to nephrology ·William F. Keane, Joanne E. Tomassini, David Neff	2011	23
11	Intestinal sterol transporters and cholesterol absorption inhibition Current Opinion in Lipidology ·Harry R. Davis, Andrew M. Tershakovec, Joanne E. Tomassini, (unknown)	2011	19
12	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction Journal of clinical lipidology ·Peter P. Tóth, Christie M. Ballantyne, Michael H. Davidson, Joanne E. Tomassini, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, Xiaohan Hu, Kaan Tunceli	2011	16
13	LOSS OF EARLY GAINS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOAL ATTAINMENT AMONG HIGH RISK PATIENTS Journal of the American College of Cardiology ·JoAnne M. Foody, Shiva Sajjan, Henry Hu, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, Joanne E. Tomassini, Kaan Tunceli	2010	2
14	Ezetimibe: cholesterol lowering and beyond Expert Review of Cardiovascular Therapy ·Harold Bays, David Neff, Joanne E. Tomassini, Andrew M. Tershakovec	2008	118
15	Effect of Body Mass Index and Ertapenem versus Cefotetan Prophylaxis on Surgical Site Infection in Elective Colorectal Surgery Surgical Infections ·Kamal M.F. Itani, Erin Jensen, Tyler S. Finn, Joanne E. Tomassini, Murray A. Abramson	2008	42
16	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia Journal of the American College of Cardiology ·John R. Guyton, B. Greg Brown, Sergio Fazio, Adam B. Polis, Joanne E. Tomassini, Andrew M. Tershakovec	2008	67
17	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company. The American Journal of Cardiology ·Scott Conard, Harold Bays, Lawrence A. Leiter, Steven Bird, Joseph Rubino, Robert S. Lowe, Joanne E. Tomassini, Andrew M. Tershakovec	2008	62
18	Randomized, Multicenter, Double-Blind Study of Efficacy, Safety, And Tolerability of Intravenous Ertapenem Versus Piperacillin/Tazobactam in Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults Surgical Infections ·Nicholas Namias, Joseph S. Solomkin, Erin Jensen, Joanne E. Tomassini, Murray A. Abramson	2007	42
19	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Current Medical Research and Opinion ·Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec	2006	92
20	[6] Expression, purification, and characterization of orthomyxovirus: Influenza transcriptase Methods in enzymology on CD-ROM/Methods in enzymology ·Joanne E. Tomassini	1996	4

About Joanne E. Tomassini

Joanne E. Tomassini is a scholar working on Endocrinology, Diabetes and Metabolism, Virology, Surgery, Cancer Research and Infectious Diseases, having authored 103 papers that have together received 4.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (59 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (33 papers), Cancer, Lipids, and Metabolism (20 papers), Pharmaceutical Economics and Policy (17 papers), Computational Drug Discovery Methods (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers), Health Systems, Economic Evaluations, Quality of Life (8 papers) and Viral Infections and Immunology Research (8 papers). The work is most often cited by research in Virology (467 citations), Infectious Diseases (1.3k citations), Hepatology (455 citations), Endocrinology, Diabetes and Metabolism (538 citations) and Epidemiology (1.1k citations). Joanne E. Tomassini has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Andrew M. Tershakovec, Richard J. Colonno, David Neff, Daria J. Hazuda, Andrew M. Tershakovec, Osvaldo Flores, J C Hastings, Gary Lee, Harold Bays and Adam B. Polis. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, The American Journal of Cardiology, Journal of the American College of Cardiology and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact